Increase of urinary 5-hydroxyindoleacetic acid excretion but not serum chromogranin A following over-the-counter 5-hydroxytryptophan intake

Canadian Journal of Gastroenterology

Volumn 22, Issue 1, 2008, Pages 49-53

  Joy, Tisha ^a   Walsh, Grace ^a   Tokmakejian, Sonya ^b   Van Uum, Stan H M ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b WESTERN UNIVERSITY   (Canada)

Author keywords

5 hydroxyindoZeacetic acid; 5 hydroxytryptophan; Carcinoid; Chromogranin A

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; 5 HYDROXYTRYPTOPHAN; ANTITUSSIVE AGENT; CAFFEINE; CHLORPROMAZINE; CHROMOGRANIN A; DEXAMPHETAMINE; DEXTROMETHORPHAN; DIMETAPP; EPHEDRINE; FLUOROURACIL; GUAIFENESIN; MELATONIN; MELPHALAN; MESALAZINE; METHOCARBAMOL; NAPROXEN; NICOTINE; NON PRESCRIPTION DRUG; PARACETAMOL; PHENACETIN; PHENOBARBITAL; PHENOTHIAZINE; PLACEBO; RATIO THEO BRONC; RESERPINE; UNCLASSIFIED DRUG; WARFARIN;

ADULT; ARTICLE; BEDTIME DOSAGE; CARCINOID; CLINICAL TRIAL; COMMUNITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIAGNOSTIC TEST; DOUBLE BLIND PROCEDURE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION; VOLUNTEER;

EID: 40749110574     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2008/472159     Document Type: Article

References (24)

1. Feldman JM. Urinary serotonin in the diagnosis of carcinoid tumors. Clin Chem 1986;32:840-4.
2. Oberg K. Carcinoid tumors, carcinoid syndrome, and related disorders. In: Larsen PR, Kronenberg HM, Melmed S, et al, eds. Williams Textbook of Endocrinology, 10th edn. Philadelphia: Elsevier Science, 2003:1857-76.
3. Nobels FRE, Kwekkeboom DJ, Coopmans W, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: Comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997;82:2622-8.
4. Nehar D, Lombard-Bohas C, Olivieri S, et al. Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxf) 2004;60:644-52.
5. Shaw K, Turner J, Del Mar C. Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database of Syst Rev 2002: CD003198.
6. Cangiano C, Ceci F, Cascino A, et al. Eating behaviour and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan. Am J Clin Nutr 1992;56:863-7.
7. Cangiano C, Ceci F, Cairella M, et al. Effects of 5-hydroxytryptophan on eating behaviour and adherence to dietary prescriptions in obese adult subjects. Adv Exp Med Biol 1991;294:591-3.
8. Ceci F, Cangiano C, Ciarella M, et al. The effects of oral 5-hydroxytryptophan administration on feeding behavior in obese adult female subjects. J Neural Transm 1989;76:109-17.
9. Hartmann E, Lindsley JG, Spinweber C. Chronic insomnia: Effects of tryptophan, flurazepam, secobarbital, and placebo. Psychopharmacology (Berl) 1983;80:138-42.
10. Schruers K, van Diest R, Overbeek T, Griez E. Acute L-5-hydroxytryptophan administration inhibits carbon dioxide-induced panic in panic disorder patients. Psychiatry Res 2002;113:237-43.
11. Braunwald E, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Stone RM. Harrison's Principles of Internal Medicine, 15th edn. New York: McGraw-Hill Professional, 2001.
12. Joseph MH, Baker HF. The determination of 5-hydroxytryptophan and its metabolites in plasma following administration to man. Clin Chim Acta 1976;72:125-31.
13. Amamoto T, Sarai K. On the tryptophan-serotonin metabolism in manic-depressive disorders. Changes in plasma 5-HT and 5-HIAA levels and urinary 5-HIAA excretion following oral loading of L-5HTP in patients with depression. Hiroshima J Med Sci 1976;25:135-40.
14. Takahashi S, Takahashi R, Masumura I, Miike A. Measurement of 5-hydroxyindole compounds during L-5-HTP treatment in depressed patients. Folia Psychiatr Neurol Jpn 1976;30:463-73.
15. Westenberg HG, Gerritsen TW, Meijer BA, van Praag HM. Kinetics of 1-5-hydroxytryptophan in healthy subjects. Psychiatry Res 1982;7:373-85.
16. Feldman JM, Lee EM. Serotonin content of foods: Effect on urinary excretion of 5-hydroxyindoleacetic acid. Am J Clin Nutr 1985;42:639-43.
17. De Vries EG, Kema IP, Slooff MJ, et al. Recent developments in diagnosis and treatment of metastatic carcinoid tumors. Scand J Gastroenterol Suppl 1993;200:87-93.
18. Sanduleanu S, Stridsberg M, Jonkera D, et al. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: A case-control study. Aliment Pharmacol Ther 1999;13:145-53.
19. Giusti M, Sidoti M, Augeri C, Rabitti C, Minuto F. Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. Eur J Endocrinol 2004;150:299-303.
20. Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med 2003;348:1134-49.
21. Syversen U, Ramstad H, Gamme K, Qvigstad G, Falkmer S, Waldum HL. Clinical significance of elevated serum chromogranin A levels. Scand J Gastroenterol 2004;39:969-73.
22. Magnussen I, Nielsen-Kudsk F. Bioavailability and related pharmacokinetics in man of orally administered L-5-hydroxytryptophan in steady state. Acta Pharmacol Toxicol (Copenh) 1980;46:257-62.
23. Meijer WG, Kema IP, Volmer M, Willemse PH, de Vries EG. Discriminating capacity of indole markers in the diagnosis of carcinoid tumors. Clin Chem 2000;46:1588-96.
24. Carling RS, Degg TJ, Allen KR, Bax ND, Barth JH. Evaluation of whole blood serotonin and plasma and urine 5-hydroxyindole acetic acid in diagnosis of carcinoid disease. Ann Clin Biochem 2002;39:577-82.